CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes Lifestyle Modifications for Preventing and Treating Heart Failure When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure

Original ResearchVolume 3, Issue 5, October 2018

JOURNAL:JACC: Basic to Translational Science Article Link

Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors

S Verma, S Rawat, KL Ho et al. Keywords: cardiac efficiency; db/db; glucose oxidation; ketone oxidation; sodium-glucose co-transporter-2 inhibitors

FULL TEXT PDF